"Designing Growth Strategies is in our DNA"

Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027

Last Updated: October 28, 2024 | Format: PDF | Report ID: FBI104668

 

  1. . Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
    2. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
    3. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
    4. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
    5. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
    6. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
    7. Impact of Covid-19 on the Market
  5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Prophylaxis
        1. Palivizumab
        2. Nirsevimab
        3. MK-1654
        4. Other Prophylaxis (Vaccines)
      2. Treatment
        1. Ribavirin
        2. All New Treatment
          1. JNJ 53718678
          2. Enanta EDP-938
          3. ASCENIV
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country
      1. North America
      2. Europe
      3. Asia pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Prophylaxis
        1. Palivizumab
        2. Nirsevimab
        3. MK-1654
        4. Other Prophylaxis (Vaccines)
      2. Treatment
        1. Ribavirin
        2. All New Treatment
          1. JNJ 53718678
          2. Enanta EDP-938
          3. ASCENIV
    3. Market Analysis – By End User
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis – By Country
      1. U.S.
      2. Canada
  7. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Prophylaxis
        1. Palivizumab
        2. Nirsevimab
        3. MK-1654
        4. Other Prophylaxis (Vaccines)
      2. Treatment
        1. Ribavirin
        2. All New Treatment
          1. JNJ 53718678
          2. Enanta EDP-938
          3. ASCENIV
    3. Market Analysis – By End User
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis – By Country
      1. U.K.
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Prophylaxis
        1. Palivizumab
        2. Nirsevimab
        3. MK-1654
        4. Other Prophylaxis (Vaccines)
      2. Treatment
        1. Ribavirin
        2. All New Treatment
          1. JNJ 53718678
          2. Enanta EDP-938
          3. ASCENIV
    3. Market Analysis – By End User
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis – By Country
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Prophylaxis
        1. Palivizumab
        2. Nirsevimab
        3. MK-1654
        4. Other Prophylaxis (Vaccines)
      2. Treatment
        1. Ribavirin
        2. All New Treatment
          1. JNJ 53718678
          2. Enanta EDP-938
          3. ASCENIV
    3. Market Analysis – By End User
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis – By Country
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Prophylaxis
        1. Palivizumab
        2. Nirsevimab
        3. MK-1654
        4. Other Prophylaxis (Vaccines)
      2. Treatment
        1. Ribavirin
        2. All New Treatment
          1. JNJ 53718678
          2. Enanta EDP-938
          3. ASCENIV
    3. Market Analysis – By End User
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis – By Country
      1. GCC Countries
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2019)
    3. Competition Dashboard
    4. Comparative Analysis – Major Players
    5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
      1. AstraZeneca
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      2. Bausch Health Companies Inc
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      3. AbbVie
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      4. Johnson & Johnson Services, Inc.
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      5. Sanofi
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      6. Merck & Co., Inc
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      7. Celltrion Inc.
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      8. mAbxience
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      9. Enanta Pharmaceuticals, Inc
        1. Overview,
        2. Products & services,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
  12. Strategic Recommendations
Read Less

Figure 1:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue Breakdown (USD Million, %) by Region, 2019 & 2027

Figure 2:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019 & 2027

Figure 3:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Prophylaxis, 2016-2027

Figure 4:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Treatment, 2016-2027

Figure 5:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Palivizumab, 2016-2027

Figure 6:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Nirsevimab, 2016-2027

Figure 7:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by MK-1654, 2016-2027

Figure 8:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Other Prophylaxis, 2016-2027

Figure 9:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Ribavirin, 2016-2027

Figure 10:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by JNJ 53718678, 2016-2027

Figure 11:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Enanta EDP-938, 2016-2027

Figure 12:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by ASCENIV4, 2016-2027

Figure 13:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019 & 2027

Figure 14:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Hospital Pharmacies, 2016-2027

Figure 15:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Retail Pharmacies, 2016-2027

Figure 16:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Online Pharmacies, 2016-2027

Figure 17:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Region, 2019 & 2027

Figure 18:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 19:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 20:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 21:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 22:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country, 2019 & 2027

Figure 23:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country, 2019

Figure 24:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 25:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 26:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 27:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 28:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 29:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 30:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 31:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 32:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 33:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 34:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 35:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 36:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 37:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 38:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 39:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 40:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 41:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 42:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 43:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 44:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 45:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 46:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 47:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 48:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share (%), By Company, 2019

Table 1:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016–2027

Table 2:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 3:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 4:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016–2027

Table 5:  Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Region, 2016-2027

Table 6:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 7:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 8:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 9:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 10:  North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country, 2016-2027

Table 11:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 12:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 13:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 14:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 15:  Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Table 16:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 17:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 18:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 19:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 20:  Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Table 21:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 22:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 23:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 24:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 25:  Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Table 26:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 27:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 28:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 29:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 30:  Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share and Global Industry Trend Forecast till 2027
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
  • Buy Now

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Related Reports

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X